Stockscreener 앱 받기
12.85
0.85%
-0.11
시간 외 거래:
12.85
전일 마감가:
$12.96
열려 있는:
$12.95
하루 거래량:
415.97K
Relative Volume:
0.68
시가총액:
$896.15M
수익:
$62.71M
순이익/손실:
$-112.51M
주가수익비율:
-8.5099
EPS:
-1.51
순현금흐름:
$-96.01M
1주 성능:
-0.23%
1개월 성능:
+17.35%
6개월 성능:
-12.35%
1년 성능:
+39.67%
1일 변동 폭
$12.76
$13.05
1주일 범위
$12.48
$13.23
52주 변동 폭
$8.21
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
ZYME을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
12.85 | 896.15M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Envestnet Asset Management Inc. - Defense World
Invesco Ltd. Reduces Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Q2 Earnings Forecast for Zymeworks Issued By Leerink Partnrs - Defense World
A new trading data show Zymeworks BC Inc (ZYME) is showing positive returns. - Sete News
Zymeworks (ZYME) Expected to Announce Earnings on Thursday - Defense World
Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline - Seeking Alpha
Zymeworks: Poised For Growth With Platform Validation - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
JPMorgan Chase & Co. Grows Stake in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting - Koreabizwire
Zymeworks Presents New Data from Multiple Development Programs a - GuruFocus
Zymeworks Inc. Presents Promising Preclinical Data on Antibody-Drug Conjugates and T Cell Engagers at AACR Annual Meeting 2025 - Nasdaq
Zymeworks Unveils Breakthrough Cancer Drug Data: T-Cell Engagers Show Strong Activity in Lung, Ovarian Cancers - Stock Titan
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - The Financial World
Zymeworks appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - MediaNews4U
Zymeworks Strengthens Clinical Leadership with New Senior VP Appointment - TipRanks
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Cl - GuruFocus
Zymeworks Strengthens Cancer Drug Pipeline: Top Oncology Expert Takes Helm of Clinical Development - Stock Titan
Major Investment Alert: Ecor1 Capital Boosts Stake in Zymeworks! - TipRanks
Zymeworks to Announce Q1 2025 Financial Results and Host Conference Call - TipRanks
Zymeworks to Report First Quarter 2025 Financial Results and Ho - GuruFocus
Zymeworks Inc. to Announce First Quarter 2025 Financial Results on May 8, 2025 - Nasdaq
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire
Clinical-Stage Biotech Zymeworks Sets Q1 2025 Earnings Date: Key Updates Expected - Stock Titan
Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout - Yahoo Finance
20 Stocks Insiders Bought in April After Trump’s Tariff Rollout - Insider Monkey
Zymeworks sees $3.62 million stock purchase by EcoR1 Capital - Investing.com Nigeria
Zymeworks Announces Participation in Upcoming Investor Conferences, Business Wires News - AsiaOne
Zymeworks Inc. sees insider purchases totaling $1.5 million By Investing.com - Investing.com South Africa
Major Investment Alert: Director Buys Big in Zymeworks! - TipRanks
Zymeworks Inc. sees insider purchases totaling $1.5 million - Investing.com
Ecor1 Capital, Llc Purchases 22,689 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Major Investment Alert: Ecor1 Capital Buys Big in Zymeworks! - TipRanks
Ecor1 Capital’s Oleg Nodelman buys $1.23 million in Zymeworks stock By Investing.com - Investing.com Canada
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Clinical-Stage Biotech Zymeworks Reveals New Pipeline Insights at Two Major Healthcare Conferences - Stock Titan
Zymeworks to Present Promising Cancer Therapy Data at AACR Meeting - TipRanks
Zymeworks to Present Preclinical Data on T cell Engager and - GlobeNewswire
Game-Changing Cancer Drug Results: Zymeworks Reveals 6 Promising Treatments at AACR - Stock Titan
Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):